Search Results - "Balato, Anna"

Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.

Authors: Balato, Anna Burlando, Martina Campanati, Anna et al.

Source: Dermatology & Therapy. Nov2025, Vol. 15 Issue 11, p3089-3108. 20p.

Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis).

Authors: Burlando, Martina Sacchelli, Lidia Bettacchi, Alberta et al.

Source: Journal of Clinical Medicine. Jun2026, Vol. 15 Issue 11, p4168. 14p.

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study.

Authors: Torres, Tiago Sood, Siddhartha Yilmaz, Orhan et al.

Source: Dermatology & Therapy. Feb2026, Vol. 16 Issue 2, p701-707. 7p.

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study.

Authors: Vignoli, Carlo A. Gargiulo, Luigi Ibba, Luciano et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-4. 4p.

Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes—IL PSO (Italian Landscape Psoriasis).

Authors: Ibba, Luciano Di Giulio, Sara Malagoli, Piergiorgio et al.

Source: Dermatology & Therapy. Apr2026, Vol. 16 Issue 4, p2169-2180. 12p.

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Authors: Gargiulo, Luigi Costanzo, Antonio Malagoli, Piergiorgio et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3331-3344. 14p.

Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).

Authors: Potestio, Luca Patruno, Cataldo Ferrucci, Silvia Mariel et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3493-3511. 19p.

Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study.

Authors: Balato, Anna Venturini, Marina Scalvenzi, Massimiliano et al.

Source: Dermatology & Therapy. Jul2025, Vol. 15 Issue 7, p1771-1785. 15p.

Adalimumab-induced facial erysipelas and its successful resolution with azithromycin in a 19-year-old female.

Authors: Giorgio, Caterina Mariarosaria Balato, Anna Licata, Gaetano et al.

Source: Dermatology Reports. 2025, Vol. 17 Issue 3, p1-4. 4p.

Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.

Authors: Megna, Matteo Balato, Anna Caccavale, Stefano et al.

Source: Journal of Clinical Medicine. May2024, Vol. 13 Issue 9, p2552. 9p.

Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study.

Authors: Mortato, Edoardo Talamonti, Marina Marcelli, Lorenzo et al.

Source: Dermatology & Therapy. May2025, Vol. 15 Issue 5, p1239-1250. 12p.

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort.

Authors: Alvarenga, José Miguel Yeung, Jensen Prajapati, Vimal et al.

Source: Dermatology & Therapy. Feb2026, Vol. 16 Issue 2, p1399-1409. 11p.

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis).

Authors: Gargiulo, Luigi Ibba, Luciano Cascio Ingurgio, Ruggero et al.

Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-5. 5p.

Commentary: Unmet Needs in Generalized Pustular Psoriasis in Clinical Practice.

Authors: Balato, Anna Ambrogio, Francesca Burlando, Martina et al.

Source: Dermatology & Therapy. Jan2024, Vol. 14 Issue 1, p5-13. 9p.

A Familial Novel Putative-Pathogenic Mutation Identified in Plaque-Psoriasis by a Multigene Panel Analysis.

Authors: Nunziato, Marcella Balato, Anna Ruocco, Anna et al.

Source: International Journal of Molecular Sciences. Mar2023, Vol. 24 Issue 5, p4743. 8p.

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis).

Authors: Gargiulo, Luigi Ibba, Luciano Alfano, Angela et al.

Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-5. 5p.

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.

Authors: Torres, Tiago Yeung, Jensen Prajapati, Vimal H. et al.

Source: Dermatology & Therapy. Aug2025, Vol. 15 Issue 8, p2295-2305. 11p.

Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors.

Authors: Gori, Niccolò Di Nardo, Lucia Ippoliti, Elena et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-7. 7p.

Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis).

Authors: Valenti, Mario Ibba, Luciano Di Giulio, Sara et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-6. 6p.

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis).

Authors: Gioacchini, Helena Rossi, Agnese Esposito, Maria et al.

Source: Dermatology & Therapy. Jul2025, Vol. 15 Issue 7, p1797-1811. 15p.